Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,733 | 2 | 40.1% |
| Travel and Lodging | $4,617 | 5 | 32.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,000 | 1 | 14.0% |
| Food and Beverage | $1,548 | 21 | 10.8% |
| Education | $400.58 | 7 | 2.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $5,846 | 3 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $4,813 | 10 | $0 (2017) |
| Rigel Pharmaceuticals, Inc. | $2,092 | 3 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $390.59 | 6 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $239.08 | 4 | $0 (2020) |
| Genentech USA, Inc. | $198.09 | 2 | $0 (2022) |
| Heron Therapeutics, Inc. | $137.20 | 1 | $0 (2018) |
| Seattle Genetics, Inc. | $124.03 | 1 | $0 (2018) |
| Kite Pharma, Inc. | $121.85 | 1 | $0 (2019) |
| Janssen Biotech, Inc. | $111.82 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35.12 | 1 | Mirati Therapeutics, Inc. ($35.12) |
| 2022 | $284.84 | 4 | Genentech USA, Inc. ($198.09) |
| 2021 | $291.65 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($291.65) |
| 2020 | $153.65 | 4 | E.R. Squibb & Sons, L.L.C. ($141.20) |
| 2019 | $2,214 | 4 | Rigel Pharmaceuticals, Inc. ($2,092) |
| 2018 | $6,232 | 7 | Celgene Corporation ($5,846) |
| 2017 | $5,087 | 13 | Bayer HealthCare Pharmaceuticals Inc. ($4,813) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/10/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $35.12 | General |
| Category: Oncology | ||||||
| 11/07/2022 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $78.73 | General |
| 05/10/2022 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $119.36 | General |
| 04/06/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Education | In-kind items and services | $67.95 | General |
| 04/01/2022 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2021 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $91.67 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Education | In-kind items and services | $99.99 | General |
| 07/23/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Education | In-kind items and services | $99.99 | General |
| 11/18/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.45 | General |
| Category: Oncology | ||||||
| 08/25/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $10.60 | General |
| Category: Oncology | ||||||
| 07/15/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $10.60 | General |
| Category: Oncology | ||||||
| 02/19/2020 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $120.00 | General |
| 08/21/2019 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: Hematology | ||||||
| 08/10/2019 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: Hematology | ||||||
| 08/10/2019 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $42.30 | General |
| Category: Hematology | ||||||
| 02/28/2019 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $121.85 | General |
| Category: ONC | ||||||
| 10/11/2018 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $3,850.00 | General |
| 10/11/2018 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $1,732.50 | General |
| 10/01/2018 | Celgene Corporation | — | Travel and Lodging | In-kind items and services | $263.96 | General |
| 08/15/2018 | Heron Therapeutics, Inc. | SUSTOL (Drug) | Food and Beverage | In-kind items and services | $137.20 | General |
| Category: CINV | ||||||
| 06/12/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $124.03 | General |
| Category: Oncology | ||||||
| 04/26/2018 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $111.82 | General |
| Category: Oncology | ||||||
| 04/03/2018 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $12.19 | General |
| Category: Oncology | ||||||
| 12/08/2017 | Bayer HealthCare Pharmaceuticals Inc. | Non-Covered | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 12/08/2017 | Bayer HealthCare Pharmaceuticals Inc. | Non-Covered | Travel and Lodging | In-kind items and services | $212.06 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 535 | 990 | $322,360 | $92,890 |
| 2022 | 10 | 556 | 1,021 | $290,916 | $87,645 |
| 2021 | 9 | 471 | 910 | $220,060 | $79,597 |
| 2020 | 10 | 609 | 1,043 | $234,921 | $71,138 |
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 2 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 22 | $3,234 | $1,342 | 41.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 16 | 21 | $3,150 | $1,108 | 35.2% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 22 | 25 | $2,275 | $646.59 | 28.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 209 | 540 | $119,880 | $32,924 | 27.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 51 | 55 | $22,660 | $9,298 | 41.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 66 | 96 | $28,608 | $8,764 | 30.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 55 | 55 | $23,375 | $7,800 | 33.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 62 | 73 | $10,950 | $2,576 | 23.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 28 | 42 | $6,174 | $2,508 | 40.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 24 | $5,064 | $2,069 | 40.9% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 67 | 92 | $7,804 | $1,990 | 25.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 35 | 41 | $5,240 | $1,641 | 31.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 23 | 25 | $5,166 | $1,568 | 30.4% |
About Dr. Abhishek Kalla, M.D
Dr. Abhishek Kalla, M.D is a Hematology & Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1508085887.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Abhishek Kalla, M.D has received a total of $14,299 in payments from pharmaceutical and medical device companies, with $35.12 received in 2024. These payments were reported across 36 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($5,733).
As a Medicare-enrolled provider, Kalla has provided services to 2,171 Medicare beneficiaries, totaling 3,964 services with total Medicare billing of $331,270. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Baltimore, MD
- Active Since 04/24/2007
- Last Updated 04/25/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1508085887
Products in Payments
- Non-Covered $4,813
- Tavalisse (Drug) $2,092
- SUSTOL (Drug) $137.20
- ADCETRIS (Biological) $124.03
- NINLARO (Drug) $122.66
- Yescarta (Drug) $121.85
- IMBRUVICA (Drug) $111.82
- EMPLICITI (Biological) $97.88
- KRAZATI (Drug) $35.12
- OPDIVO (Biological) $21.20
- XPOVIO (Drug) $12.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Baltimore
Miss. Ani Balmanoukian, M.d, M.D
Hematology & Oncology — Payments: $842,199
Dr. Benjamin Levy, Md, MD
Hematology & Oncology — Payments: $814,882
Dr. Patrick Forde, M.d, M.D
Hematology & Oncology — Payments: $253,665
Josephine Feliciano, M.d, M.D
Hematology & Oncology — Payments: $125,936
Djordje Atanackovic, M.d, M.D
Hematology & Oncology — Payments: $117,434
Huzefa Bahrain, D.o, D.O
Hematology & Oncology — Payments: $103,816